A case of autoinflammatory skin and bone disease flared by a change in osteoporosis management

Heard, L. Kevin; Richardson, Vanessa N.; Lewis, Caroline M.; Davis, Loretta S.

doi:10.1016/j.jdcr.2017.01.004

Cited by 2 publications

(2 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A total of 3212 unique citations were found. 1286 and 1704 citations were excluded by abstract and full‐text read, respectively, yielding 222 articles…”

Section: Resultsmentioning

confidence: 99%

Pyoderma gangrenosum and tumour necrosis factor alpha inhibitors: A semi‐systematic review

Abdallah

Fogh

Bech

2019

International Wound Journal

View full text Add to dashboard Cite

Pyoderma gangrenosum (PG) is a rare ulcerative skin disease that presents a therapeutic challenge. Tumour necrosis factor alpha (TNFα) inhibitors have been reported to successfully control PG. Our aim was to systematically evaluate and compare the clinical effectiveness of TNFα inhibitors in adults with PG. A literature search including databases such as PubMed, Embase, Scopus, and Web of Science was conducted, using search terms related to PG and TNFα inhibitors. Studies and case reports were included if patients were diagnosed with PG, over the age of 18 and administered TNFα inhibitor. A total of 3212 unique citations were identified resulting in 222 articles describing 356 patients being included in our study. The study we report found an 87% (95% CI: 83%‐90%) response rate and a 67% (95% CI: 62%‐72%) complete response rate to TNFα inhibitors. No statistically significant differences in the response rates (P = 0.6159) or complete response rates (P = 0.0773) to infliximab, adalimumab, and etanercept were found. In our study TNFα inhibitors demonstrated significant effectiveness with response and complete response rates supporting the use of TNFα inhibitors to treat PG in adults. Our study suggests that there is no significant difference in effectiveness among infliximab, adalimumab, and etanercept.

show abstract

“…A total of 3212 unique citations were found. 1286 and 1704 citations were excluded by abstract and full‐text read, respectively, yielding 222 articles…”

Section: Resultsmentioning

confidence: 99%

Pyoderma gangrenosum and tumour necrosis factor alpha inhibitors: A semi‐systematic review

Abdallah

Fogh

Bech

2019

International Wound Journal

View full text Add to dashboard Cite

show abstract

“…Table 2 with excluded publications with reasons of exclusion), resulting in the inclusion of 60 publications describing 81 patients (online suppl. Tables 3 and 4) [3, 5, 13‒70].…”

Section: Resultsmentioning

confidence: 99%

Pyoderma Gangrenosum and Interleukin Inhibitors: A Semi-Systematic Review

et al. 2021

View full text Add to dashboard Cite

Background: Pyoderma gangrenosum (PG) is a rare ulcerating skin disease associated with multiple comorbidities and increased mortality. In recent decades, newer biologics such as interleukin inhibitors have been used to treat PG; however, the literature is scarce, consisting predominantly of case reports and caseseries. The aim of our review was to evaluate the effectiveness and safety of interleukin inhibitors for the treatment of PG in adults. Summary: A literature search was conducted using search terms related to PG and interleukin inhibitors in databases such as PubMed, Embase, Scopus, Web of Science, and Cochrane Library. The study eligibility criteria included patients diagnosed with PG, over the age of 18, and treated with an interleukin inhibitor. Our study included 60 papers describing 81 patients fulfilling the eligibility criteria. The treatment with interleukin inhibitors resulted in 70% (95% CI 59–80%) response and 57% (95% CI 45–68%) complete response rates, and few (4%) mild adverse events, hence supporting the off-label use for the treatment of recalcitrant PG in adults. The response and complete response rates were 59% (17/29) and 38% (11/29) for anakinra, 64% (7/11) and 55% (6/11) for canakinumab, and 79% (27/34) and 71% (24/34) for ustekinumab, respectively. Limitations include publication bias that might have overestimated the efficacy as successful cases responding to treatment are more likely to be reported than nonresponding cases. Additionally, the heterogeneity of the treatment groups does not allow conclusions of superiority or inferiority of the different interleukin inhibitors to be drawn. Further studies are needed to investigate the efficacy of the different interleukin inhibitors and to investigate the importance of underlying disease for treatment response.

show abstract

A case of autoinflammatory skin and bone disease flared by a change in osteoporosis management

Cited by 2 publications

References 8 publications

Pyoderma gangrenosum and tumour necrosis factor alpha inhibitors: A semi‐systematic review

Pyoderma gangrenosum and tumour necrosis factor alpha inhibitors: A semi‐systematic review

Pyoderma Gangrenosum and Interleukin Inhibitors: A Semi-Systematic Review

Contact Info

Product

Resources

About